|Day Low/High||94.70 / 97.89|
|52 Wk Low/High||27.52 / 58.52|
The next time you are shaken out because of the action I need you to remember these examples.
The intense rally in NUE makes it look like a cloud or tech name.
Sure you can but any of these, but do not buy all of them because you will be betting against the business cycle.
Getting dizzy looking down from here? Then look up, because we may just be getting started on this market.
It might be too difficult for Jay Powell NOT to raise rates now that the Great Reopening is upon us.
It looks like I will continue to wait before recommending the long side of MLM.
One of the most continual themes in this market is that anything that was liked last year is hated this year.
Here's where there might be a buying opportunity.
We're headed to Boom Town, so let me show you how to line up your ticket -- and the best picks for the great reopening.
The fears of what would happen from Democratic wins in Georgia's race failed to pan out, aside from tech taking a few hits. Here's what's happening instead and why.
The fact is that business in whole areas of the economy remain very strong despite what you heard about ZM this morning.
Beyond the impacts of the pandemic, the political environment and its impact on potential policy have taken center stage.
The steelmaker's charts aren't screaming that it is time to buy its shares.
The steelmaker is in an uptrend but I'm not really excited about going long at current levels.
Earnings are coming, and I suggest waiting at this point on the ones that are up, but buying those that are flat to down.
The buyers have decided that the researchers and doctors are going to beat the virus, so you better get on board or miss the move.
The charts of the steel company are positive right now.
If a trillion dollar package were to happen, here are the companies -- and communities -- who would benefit most.
Let's step back and look at this market that has abandoned all sorts of safety and went all in on the stocks of companies based on the Fed's words and a promising Moderna study.
Let's review the charts and indicators once again.